These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16509549)

  • 1. Cost-effectiveness strategies to treat osteoporosis in elderly women.
    Pfister AK; Welch CA; Lester MD; Emmett MK; Saville PD; Duerring SA
    South Med J; 2006 Feb; 99(2):123-31. PubMed ID: 16509549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
    Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
    Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The necessity of cost-effectiveness analysis in osteoporosis].
    Lamy O; Krieg MA
    Rev Med Suisse; 2007 Jun; 3(115):1521-5. PubMed ID: 17682796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
    Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
    Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia.
    Meadows ES; Klein R; Rousculp MD; Smolen L; Ohsfeldt RL; Johnston JA
    BMC Womens Health; 2007 Apr; 7():6. PubMed ID: 17439652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
    Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
    J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
    Jansen JP; Gaugris S; Bergman G; Sen SS
    Curr Med Res Opin; 2008 Mar; 24(3):671-84. PubMed ID: 18221588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
    Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
    JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential clinical and economic impact of nonadherence with osteoporosis medications.
    Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
    Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
    Goeree R; Blackhouse G; Adachi J
    Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of different treatments for osteoporosis on prevention of fractures: toward and individualized and economic approach].
    Lamy O; Krieg MA
    Praxis (Bern 1994); 2004 Mar; 93(11):399-405. PubMed ID: 15061107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
    Fleurence RL; Iglesias CP; Johnson JM
    Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.
    Hiligsmann M; Vanoverberghe M; Neuprez A; Bruyère O; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):359-66. PubMed ID: 20715911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.
    Lippuner K; Pollock RF; Smith-Palmer J; Meury T; Valentine WJ
    Appl Health Econ Health Policy; 2011 Nov; 9(6):403-17. PubMed ID: 21910511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.
    van Staa TP; Geusens P; Zhang B; Leufkens HG; Boonen A; Cooper C
    Rheumatology (Oxford); 2007 Mar; 46(3):460-6. PubMed ID: 16899499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is treatment of early postmenopausal women with bisphosphonates justified?
    Epstein S
    Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
    Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
    Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.